Sage Bionetworks Strikes Deal With Pfizer to Find Cancer Drug Targets

1/11/10Follow @xconomy

(Page 2 of 2)

his share of skepticism. One fallacy he’s heard is that Sage is a stealthy “Merck project” to benefit Friend’s former employer. He’s hopeful that cutting the deal with Pfizer will help lay that notion to rest.

“A lot of people have wondered whether any pharmaceutical company would be interested in Sage Bionetworks, or whether it was just a few academics and Merck,” Friend says. “To our minds, this validates us.”

Still, I can imagine this deal opening up Sage to some criticism for backing away a bit from its pure open-source collaborative mission. The data that Sage and Pfizer generate from their partnership will get dumped into Sage’s public data repository, but not until one year after a given project concludes, Friend says. That sounds like it would give Pfizer scientists a pretty sizable head start over other biologists—exactly what you’d expect from a profit-driven organization that wants to keep a lot of its research proprietary.

Our conversation was a bit rushed, so I didn’t have as much time as I’d normally like to question Friend on the details of this arrangement and how it balances Pfizer’s interests with those of the biological research world, and Sage’s need for support. But Friend insisted that Pfizer was comfortable with the way Sage has structured the deal, knowing that the computing models and data will be released into the public domain.

“People are excited to work with us knowing that it’s going in the public domain and that other eyes will be able to help build on it,” Friend says.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

  • Hans Westerhoff

    Dear Steve,
    Web talked yesterday after yor lecture in the Olof’s Chapel in Amsterdam. Invitation for similar lecture in front of the 140 postdocs/PhD students/PIS at the FEBS Advanced lecture course above Innsbruck at 1980 m above sea level in a skihut setting.
    March. Also: hook-up with Rudi Balling, Hans Lehrach,driano Henney, virtual liver, JWS live models and myself (virtual biochemical human). March 1, 2011

  • http://Vivango Valerie

    My company is technically able to develop this. Now i need an investor to make this happen a real open source independent open source platform. Any comments are welcome.

  • Cherry Gurado

    Isn’t it obvious that you try to tease academic data away from the people who may have an ethical incentive to interpret them for the common good towards unethical big pharmaceutical companies who only look for blockbuster drugs that enhance their stock price?